Sangiovanni S, et al. - Researchers analyzed relevant RCTs to determine the clinical impacts of inhaled Tobramycin in P. aeruginosa density in sputum and eradication, lung function, bacterial resistance, as well as exacerbations needing hospital admission, in the context of patients experiencing non-cystic fibrosis bronchiectasis (NCFBE) colonized by P. aeruginosa. RCTs that compared inhaled tobramycin vs other antibiotics and placebo in patients with NCFBE were included. Experts analyzed 5 studies including 211 participants. The evidence gained in this study was not robust enough to corroborate that inhaled Tobramycin is beneficial in attenuating P. aeruginosa sputum density or eradication. Findings demonstrated a high attrition rate, partly because of respiratory adverse events following drug administration, which impacts interpretation of the data as well as raises concerns regarding the tolerability of the drug.